Peptides DB
Research-centric peptide and protocol reference hub
Study 28 of 30L-Carnitine (Levocarnitine) literatureFood research international (Ottawa, Ont.) · RCT · Phase 42026

Phytosterol-enriched corn and wheat germ blended oil improves lipid metabolism in hyperlipidemia via the AMPK/PPARα/CPT1 pathway.

PCWGO may improve lipid metabolism in individuals with borderline dyslipidemia, but further research is needed to confirm these findings and assess clinical relevance.

Read at Food research international (Ottawa, Ont.)Add to compare

Where it sits

this study against the rest of the l-carnitine (levocarnitine) corpus
5
Preclinical
20
Observational
0
Open-label
3
Randomised · this one
2
Reviews

Summary and findings

This study evaluated the effects of phytosterol-enriched corn and wheat germ blended oil (PCWGO) on lipid metabolism in individuals with borderline dyslipidemia and hyperlipidemic rats. Participants received PCWGO or peanut oil for 3 months, while rats were treated for 8 weeks. Significant reductions in various lipid parameters were observed in both groups.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.n=60Phase 42026

Abstract

The authors’ words, as Food research international (Ottawa, Ont.) supplied them

<h4>Background</h4>While plant sterol-enriched oils are known to improve lipid profiles, the effects and mechanisms of phytosterol-enriched corn and wheat germ blended oil (PCWGO) remain unclear.<h4>Objective</h4>This study evaluated the lipid-regulating effects of PCWGO in individuals with borderline dyslipidemia and hyperlipidemic rats, and explored the underlying mechanisms.<h4>Methods</h4>A randomized, single-blind, parallel-controlled trial was conducted in 60 adults assigned to PCWGO or peanut oil (PO) for 3 months. Serum lipids and oxidative stress markers were measured. In parallel, high-fat diet-induced hyperlipidemic rats received PCWGO or PO for 8 weeks, followed by assessment of lipid levels, liver histology, and AMPK/PPARα/CPT1 pathway proteins.<h4>Results</h4>In the human trial, the PCWGO group showed significant reductions in serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B), along with increased superoxide dismutase (SOD), glutathione (GSH), and total antioxidant capacity (TAOC), and decreased reactive oxygen species (ROS) (P < 0.05). In hyperlipidemic rats, PCWGO similarly reduced serum TC, TG, and LDL-C after eight weeks (P < 0.05). Western blot analysis showed upregulated hepatic expression of phosphorylated AMP-activated protein kinase (p-AMPK), peroxisome proliferator-activated receptor α (PPARα), and carnitine palmitoyltransferase 1 (CPT1) in the PCWGO group versus the PO group (P < 0.05).<h4>Conclusions</h4>PCWGO effectively improved lipid metabolism in both humans and animal models and may have beneficial effects on oxidative status. Its hypolipidemic effects may be related to activation of the AMPK/PPARα/CPT1 pathway, promoting fatty acid β-oxidation. These findings support phytosterol-enriched blended germ oil as a potential dietary strategy for managing dyslipidemia.

Background

This paper addresses the effects of phytosterol-enriched oils on lipid metabolism, particularly in individuals with borderline dyslipidemia. Previous research has indicated that plant sterols can improve lipid profiles, but the specific effects and mechanisms of phytosterol-enriched corn and wheat germ blended oil (PCWGO) were not well understood. Understanding these effects is important for developing dietary strategies for managing dyslipidemia.

Methods

A randomized, single-blind, parallel-controlled trial was conducted involving 60 adults assigned to receive either PCWGO or peanut oil (PO) for 3 months. Serum lipids and oxidative stress markers were measured as primary outcomes. Additionally, hyperlipidemic rats were treated with PCWGO or PO for 8 weeks to assess lipid levels, liver histology, and protein expression related to the AMPK/PPARα/CPT1 pathway.

Results

The PCWGO group exhibited significant reductions in serum total cholesterol, triglycerides, low-density lipoprotein cholesterol, and apolipoprotein B, with a p-value of less than 0.05. Improvements in oxidative stress markers were also noted, including increased superoxide dismutase, glutathione, and total antioxidant capacity, along with decreased reactive oxygen species, all with p-values less than 0.05. In the rat model, PCWGO similarly reduced serum total cholesterol, triglycerides, and low-density lipoprotein cholesterol after 8 weeks, with p-values less than 0.05.

Interpretation

The findings suggest that PCWGO may effectively improve lipid metabolism and oxidative status in both humans and animal models. However, while the statistical significance is noted, the clinical significance of these changes should be carefully evaluated, especially given the small sample size and potential confounding factors. The study's design and the reliance on surrogate endpoints may limit the generalizability of the results to broader populations.

Key findings

  • Significant reductions in serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in the PCWGO group, P < 0.05.
  • Increased superoxide dismutase (SOD), glutathione (GSH), and total antioxidant capacity (TAOC) in the PCWGO group, P < 0.05.
  • Decreased reactive oxygen species (ROS) in the PCWGO group, P < 0.05.
  • In hyperlipidemic rats, PCWGO reduced serum TC, TG, and LDL-C after eight weeks, P < 0.05.
  • Western blot analysis showed upregulated hepatic expression of phosphorylated AMP-activated protein kinase (p-AMPK), peroxisome proliferator-activated receptor α (PPARα), and carnitine palmitoyltransferase 1 (CPT1) in the PCWGO group versus the PO group, P < 0.05.

Limitations

  • small sample size of 60 adults
  • single-blind design
  • short follow-up duration of 3 months for human trial
  • use of surrogate endpoints
  • rat model may not fully translate to human outcomes

Elsewhere in the L-Carnitine (Levocarnitine) corpus

CMetabolic identification of carnitine biomarkers for the differential diagnosis of uterine disorders in bitches.Theriogenology · 2026 · n=39 · Not reported in abstract.AnimalCCitalopram modulates hypothalamic appetite-related signalling and hepatic lipid metabolism in rainbow trout.Comparative biochemistry and physiology. Toxicology & pharmacology : CBP · 2026 · Intraperitoneal injection induced hyperglycemia.AnimalCIntegrating in vivo metabolism, pharmacokinetics, and dual-indicator scoring for PK-marker selection of Celosiae Semen saponins.Journal of pharmaceutical and biomedical analysis · 2026 · AUC₀-∞ was 215.45 μg·min/mL.AnimalCCPT1A alters granulosa cell proliferation and steroidogenic activity in association with fatty acid oxidation during goat follicular development.Theriogenology · 2026 · Not reported in abstract.AnimalCIntegrative single-cell and bulk transcriptome analyses reveal a carnitine-related prognostic signature and fibroblast plasticity in HNSCCbiorxiv-preprint · 2026 · The risk model achieved 1-, 3-, and 5-year AUC values of 0.65, 0.66, and 0.65 in the training set.In vitroDThe protective effect of chemical and natural compounds against amiodarone induced toxicity: A systematic review.Biochemistry and biophysics reports · 2026 · Not reported in abstract.review